Junshi Biosciences Announces Phase 3 Clinical Study of : vim

SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...

Related Keywords

Beijing , China , Uzbekistan , Jianjun , Shaanxi , Maryland , United States , Guangzhou , Guangdong , Shanghai , San Francisco , California , Hong Kong , Suzhou , Jiangsu , Chinese , Zhi Li , Junshi Biosciences , Junshi Bioscience , Ir Team , Therapeutics Inc , Drug Administration , Global Research , International Federation Of Gynecology , Shanghai Junshi Biosciences Co Ltd , Pr Team , Data Monitoring Committee , International Federation , Independent Data Monitoring Committee , Five Year Plan , Macau Special Administrative , Emergency Use Authorizations , Hong Kong Stock Exchange 1877 Hk ,